


**Remarks/Arguments**

Applicants have amended the specification to provide the priority claim. The claims have been amended to place the claims in an appropriate U.S. format. No new matter has been added by these amendments. The above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100873-1P US.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Christine McCormack', written over a horizontal line.

Name: Christine McCormack  
Dated: April 20, 2005  
Reg. No.: (Limited Recognition  
Under 37 CFR §10.9(b); See attached)  
Phone No.: 1-781-839-4693

Global Intellectual Property, Patents,  
AstraZeneca R&D Boston,  
35, Gatehouse Drive,  
Waltham, MA 01760